SDC1 and cancer: Further, another study investigating the clinical implications of circulating Syndecan-1 in PCa patients found high levels (>123 ng/mL) of soluble Syndecan-1 in the serum of more advanced PCa patients, which was correlated with worse overall and cancer-specific survival.